Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Articolo
Data di Pubblicazione:
2021
Abstract:
Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Curigliano, Giuseppe; Gelderblom, Hans; Mach, Nicolas; Doi, Toshihiko; Tai, David; Forde, Patrick M; Sarantopoulos, John; Bedard, Philippe L; Lin, Chia-Chi; Hodi, F Stephen; Wilgenhof, Sofie; Santoro, Armando; Sabatos-Peyton, Catherine A; Longmire, Tyler A; Xyrafas, Alexandros; Sun, Haiying; Gutzwiller, Sabine; Manenti, Luigi; Naing, Aung
Link alla scheda completa:
Pubblicato in: